Ticagrelol Versus Aspirin in Ischemic Stroke
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 169 participants.
Also called NCT03884530
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 169 participants
- Registry
-
NCT03884530
-
- Other papers using this trial's data
- A pilot study of the ticagrelor role in ischemic stroke secondary prevention
- A randomized pilot study of the efficacy and safety of loading ticagrelor in acute ischemic stroke
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Egypt
- Registry status
- Completed
Technical summary
Registry record NCT03884530. Randomized; no masking; primary purpose treatment. Start 2019-05-01 (actual); primary completion 2020-09-30 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Ticagrelol Versus Aspirin in Ischemic Stroke
- Condition
- Acute Stroke
- Condition
- Ischemic Stroke
- Intervention (Drug)
- Ticagrelor (Brilique) 90
- Intervention (Drug)
- Aspirin 75mg
- Lead sponsor
- Kafrelsheikh University
- Collaborator
- Ain Shams University
Record details
- Record id
cardio:ct-nct03884530- Content hash
a97ece40f55d105120f3c977e957ac520eae0931def28a1a838b7156683d47df